# Hepion Pharmaceuticals Successfully Completes Application to the OTCQB – Hepion Pharmaceuticals
Canonical URL: https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-successfully-completes-application-to-the-otcqb-hepion-ph-ebadb4d3
Ticker: HEPA
Company: Hepion Pharmaceuticals
Source: Hepion Pharmaceuticals
Published: 2026-07-09 15:57 EST
Original Source URL: https://hepionpharma.com/investors/news/
## Summary

MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac dise...

## Article Body
MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company’s common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA.

About Hepion Pharmaceuticals

Hepion is a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma.

For further information, please contact:

Hepion Pharmaceuticals info@hepionpharma.com
## Recent Company News
- 2026-07-09 15:57 EST — [Hepion Pharmaceuticals Successfully Completes Application to the OTCQB – Hepion Pharmaceuticals](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-successfully-completes-application-to-the-otcqb-hepion-ph-ebadb4d3) — Source: Hepion Pharmaceuticals
- 2026-07-09 03:05 EST — [Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq – Hepion Pharmaceuticals](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-receipt-of-delisting-notification-from-nasdaq-h-8c99f509) — Source: Hepion Pharmaceuticals
- 2026-07-09 03:05 EST — [Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer – Hepion Pharmaceuticals](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-dr-kaouthar-lbiati-as-interim-chief-executive-o-9422279d) — Source: Hepion Pharmaceuticals
- 2026-07-09 03:05 EST — [Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma – Hepion Pharmaceuticals](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-in-licenses-ctrna-biomarker-assay-to-facilitate-early-dia-ffd56961) — Source: Hepion Pharmaceuticals
- 2025-05-07 12:00 EST — [Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-executes-binding-letter-of-intent-with-new-day-diagnostic-77e3cc40) — Source: Hepion Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)